Statute Details
- Title: Medicines (Cessation of Application of Act to Therapeutic Products) Order 2016
- Act Code: MA1975-S541-2016
- Legislation Type: Subsidiary Legislation (SL)
- Enacting Authority: Minister for Health
- Authorising Act: Medicines Act (Cap. 176), section 77
- Legislative Instrument No.: SL 541/2016
- Date Made: 31 October 2016
- Key Commencement/Transition Date: 1 November 2016
- Status (as provided): Current version as at 27 Mar 2026
- Key Provisions: Section 3 (cessation), Section 4 (saving and transitional provisions)
- Schedules: First Schedule (pending applications), Second Schedule (documents issued)
What Is This Legislation About?
The Medicines (Cessation of Application of Act to Therapeutic Products) Order 2016 (“the Order”) is a transitional and “switch-over” instrument. In plain terms, it marks the point at which Singapore’s regulatory framework for certain products moves away from the Medicines Act and into the Health Products Act regime for “therapeutic products”.
Before 1 November 2016, medicinal products were regulated under the Medicines Act. From 1 November 2016, the Health Products Act framework—together with the Health Products (Therapeutic Products) Regulations 2016—takes over for products that are categorised as “therapeutic products”. This Order ensures that the transition is orderly: applications, licences, certificates, permits, and certain declarations made under the old regime are not abruptly invalidated.
Accordingly, the Order does two main things. First, it provides that the Medicines Act provisions cease to apply to therapeutic products from 1 November 2016. Second, it contains detailed saving and transitional provisions so that ongoing processes and existing authorisations continue under the new regime, with appropriate deeming and substitution rules.
What Are the Key Provisions?
1. Definitions and regulatory mapping (Section 2)
Section 2 sets out a set of definitions that “map” concepts across the two regulatory regimes. For example, it defines “health product” by reference to the Health Products Act, and “therapeutic product” by reference to the First Schedule to the Health Products Act. It also defines licence types under both regimes (e.g., “medicine manufacturer’s licence” under the Medicines Act and “health product manufacturer’s licence” under the Health Products Act). These definitions are crucial because the Order repeatedly uses “deeming” language: it converts old licence categories into new ones.
Section 2 also defines “medicinal product” as a medicinal product that falls within the category of a therapeutic product on or after 1 November 2016. This ensures the Order’s effect is targeted: it does not necessarily sweep all medicinal products into the new regime, but rather those that are categorised as therapeutic products from that date.
2. Cessation of application of the Medicines Act to therapeutic products (Section 3)
Section 3 is the core operative provision. It states that the provisions of the Medicines Act cease to apply to any therapeutic product as from 1 November 2016. In practical terms, after that date, the regulatory basis for therapeutic products is no longer the Medicines Act; instead, the Health Products Act and its subsidiary legislation govern.
This cessation clause is significant because it affects legal authority and compliance expectations. For therapeutic products, any regulatory requirement, enforcement action, or licensing pathway that previously relied on the Medicines Act would need to be re-anchored in the Health Products Act framework from 1 November 2016 onward.
3. Transitional treatment of pending applications (Section 4(1) and First Schedule)
Section 4(1) addresses applications that were pending immediately before 1 November 2016. It provides that such applications—where the medicinal product is specified in the First Schedule (first column)—are treated, on or after 1 November 2016, as applications in relation to the corresponding therapeutic product specified opposite in the second column.
For practitioners, this is a “continuity” rule. It prevents applicants from having to restart their applications from scratch. Instead, the application is effectively reclassified to fit the therapeutic product category under the new regime. The First Schedule therefore functions as a crosswalk between old medicinal product categories and new therapeutic product categories.
4. Transitional treatment of existing licences, certificates, permits, and product licences (Section 4(2)–(4))
Section 4(2) provides that every licence, certificate, or permit valid immediately before 1 November 2016 in respect of a medicinal product specified in the Second Schedule is treated, on or after that date and for so long as it remains valid, as if it were a licence/certificate/other document issued in respect of a therapeutic product as specified opposite in the Second Schedule.
Section 4(3) addresses product licences. It states that any medicinal product for which a product licence is valid immediately before 1 November 2016 is deemed to be registered as a therapeutic product under the Health Products Act for so long as the product licence remains valid. It further deems the holder of the product licence to be the “registrant” of the therapeutic product and to be subject to the duties of a registrant under the Health Products Act and the Therapeutic Products Regulations.
Section 4(4) similarly addresses persons holding licences under the Medicines Act—specifically a medicine manufacturer’s licence, import licence, or wholesale dealer’s licence. Such persons are deemed, on or after 1 November 2016 and for so long as the licence remains valid, to be holders of the corresponding Health Products Act licences (health product manufacturer’s licence, importer’s licence, or wholesaler’s licence) and to be subject to the relevant duties under the new regime.
5. Continuity of declarations/notices and other procedural instruments (Section 4(5)–(6))
Section 4(5) deals with declarations or notices made under section 12A(2) or (3)(a) of the Medicines Act in an application pending before 1 November 2016 for a product licence. It provides that such declarations/notices are treated as declarations/notices made under regulation 23(2) or (5) of the Therapeutic Products Regulations, as applicable.
This is a technical but important provision: it preserves the legal effect of procedural statements already made, ensuring that the applicant’s file does not become defective merely because the regulatory instrument changed.
Section 4(6) addresses permits granted under paragraph 5 of the Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order that were valid immediately before 1 November 2016. Such permits are deemed to be importer’s licences under the Health Products Act for so long as the permit remains valid.
6. Pharmacy registration conversion (Section 4(7))
Section 4(7) provides that every registered pharmacy from which a retail pharmacy business is conducted immediately before 1 November 2016 is deemed to be a licensed retail pharmacy for so long as the registration remains valid. This ensures that retail pharmacy operations are not disrupted by the legislative transition.
7. Saving and transitional provisions generally (Section 4)
Although Section 4 is structured as a series of specific deeming rules, the overall effect is consistent: it prevents a “regulatory cliff-edge” on 1 November 2016. The Order is designed to maintain continuity of authorisations and applications while aligning them with the new Health Products Act framework.
How Is This Legislation Structured?
The Order is short and focused, with a conventional structure for subsidiary legislation:
Enacting Formula and Citation (Section 1) identify the instrument and its legal basis.
Definitions (Section 2) provide cross-references to the Health Products Act and the relevant subsidiary regulations, and define key licence and product categories used throughout the Order.
Operative Cessation Provision (Section 3) states the date from which the Medicines Act ceases to apply to therapeutic products.
Saving and Transitional Provisions (Section 4) contains the main transitional mechanics, including deeming rules for pending applications, existing licences/certificates/permits, product licences, declarations/notices, exemption permits, and pharmacy registrations.
Schedules support the transitional provisions: the First Schedule cross-references pending applications for medicinal products to the corresponding therapeutic products; the Second Schedule cross-references existing documents (licences/certificates/permits) to the corresponding therapeutic product documents.
Who Does This Legislation Apply To?
The Order applies to (i) therapeutic products as categorised for the purposes of the Health Products Act regime, and (ii) the regulated persons and documents associated with those products during the transition period around 1 November 2016.
In practical terms, it affects:
- Applicants with pending applications immediately before 1 November 2016 for product licences relating to medicinal products that fall within the therapeutic product category.
- Holders of licences/certificates/permits valid immediately before 1 November 2016 (including product licences).
- Manufacturers, importers, and wholesalers holding Medicines Act licences that are converted into Health Products Act equivalents.
- Registrants and registrant-equivalents because product licence holders are deemed to become registrants under the Health Products Act and are subject to registrant duties.
- Retail pharmacies that are deemed to be licensed retail pharmacies.
Although the Order’s cessation clause is prospective (from 1 November 2016), its transitional provisions apply to the specific set of circumstances existing immediately before that date—meaning the Order is most relevant to historical filings and authorisations, but it continues to matter for as long as converted licences/registrations remain valid.
Why Is This Legislation Important?
This Order is important because it resolves a common legal risk during regulatory reform: what happens to existing rights and ongoing processes when the governing statute changes. Without a saving and transitional framework, regulated entities could face uncertainty about whether their authorisations remain valid, whether their applications must be refiled, and whether compliance duties have changed.
From a practitioner’s perspective, the Order provides clear deeming mechanisms that reduce administrative friction. For example, a product licence holder is not left in limbo; instead, the product is deemed registered as a therapeutic product, and the holder is deemed to be the registrant subject to the new duties. Similarly, pending applications are treated as applications for the therapeutic product category, preserving procedural continuity.
Finally, the cessation clause (Section 3) has enforcement and compliance implications. After 1 November 2016, therapeutic products are regulated under the Health Products Act framework, so practitioners must ensure that regulatory submissions, renewals, and compliance programmes are aligned with the Health Products Act and the Therapeutic Products Regulations—not the Medicines Act provisions that have ceased to apply.
Related Legislation
- Medicines Act (Cap. 176)
- Health Products Act (Cap. 122D)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6)
Source Documents
This article provides an overview of the Medicines (Cessation of Application of Act to Therapeutic Products) Order 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.